Breakthrough Cancer Therapy Moves to Phase 2 Trials

A promising cancer therapy developed by Georgia State University researchers and biotech startup Da Zen Theranostics is taking a major step forward, entering Phase 2 clinical trials. The treatment, which harnesses targeted radiation to destroy tumors with precision, could mark a turning point in how cancer is treated — and in the lives of patients who need better options.

“It’s deeply rewarding to see DZ-002 advance into Phase 2 trials, marking a promising step forward in cancer treatment and offering hope for improved patient outcomes,” says Professor of Chemistry Maged Henary, associate chair of the Department of Chemistry at Georgia State. “Knowing that this therapy could help someone live longer or feel even a little better during a difficult time is what drives us every day.”

DZ-002 is an innovative cancer treatment developed through a collaborative effort among Georgia State University, Emory University and Cedars-Sinai Medical Center.

Read more here